問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

更新時間：2023-09-19

石宇閎
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

36Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

石宇閎

List

51Cases

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
Multicenter, Phase III, Randomized, Placebo-controlled, Double-blind Study of Combination Therapy with D07001 Softgel Capsules and Capecitabine Versus Placebo and Capecitabine in Participants with Advanced Biliary Tract Cancer after Treatment Failure with Gemcitabine, Platinum, and FOLFOX or Irinotecan Regimens

  • Condition/Disease

    Biliary Tract Cancer (BTC)

  • Test Drug

    CAPECITABINE D07001-Softgel Capsules Placebo 艾結達膜衣錠 500 毫克 克癌特膜衣錠150毫克 克癌特膜衣錠500毫克 截瘤達錠５００毫克

Participate Sites
9Sites

Not yet recruiting9Sites

2025-03-01 - 2029-12-31

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-03-31 - 2028-01-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2026-03-15 - 2040-12-31

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting5Sites

2025-02-03 - 2029-12-23

Not yet recruiting
A phase 3 randomized, double-blind, placebo-controlled trial compared TPST-1120 with Atezolizumab plus Bevacizumab to placebo plus Atezolizumab plus Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who had not received systemic therapy.

  • Condition/Disease

    ● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2030-06-18

Phase III

Active
A phase III, randomized, open-label, commissioner-blinded, multicenter trial evaluating ribegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment for patients with advanced hepatocellular carcinoma (ARTEMIDE-HCC01).

  • Condition/Disease

    Advanced hepatocellular carcinoma

  • Test Drug

    Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

2021-05-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-04-01 - 2027-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2022-07-01 - 2031-04-21

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-03-01 - 2028-06-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB